Published: Jan. 1, 2024
Language: Английский
Seminars in Neurology, Journal Year: 2025, Volume and Issue: 45(02), P. 287 - 297
Published: April 1, 2025
Abstract Since the first antiseizure medication (ASM) was introduced in 1857, more than 30 medications have been approved by United States Food and Drug Administration (FDA) for treatment of epilepsy. However, limitations efficacy tolerability led to one-third patients suffering from uncontrolled seizures. Recent advances genetics, disease modeling, high-throughput target-based phenotype-based screening, study design, identification novel mechanisms action or routes delivery resulted 200 therapeutics currently under development epilepsy pipeline. This discusses near-to-market drugs advanced clinical development, with select earlier stages. Background regarding mechanisms, animal studies, pharmacokinetics, pharmacodynamics, efficacy, tolerability, safety data are provided each drug when available.
Language: Английский
Citations
0
International Journal of Innovative Science and Research Technology (IJISRT), Journal Year: 2024, Volume and Issue: unknown, P. 344 - 349
Published: April 18, 2024
Anxiety is characterized as an overwhelming sense of worry or fear for the future, while epilepsy a chronic neurological condition. Both anxiety and are prevalent conditions that impact individuals globally associated with diminished function life quality. This review article explains about treatment, etiology, pathophysiology, current advances relationship between epilepsy. Previous research suggests disorders widespread clinically relevant comorbid diseases in patients because can cause seizures may anxiety. To treat epilepsy, thorough, multidisciplinary clinical assessment required. Medication, lifestyle modifications, psychotherapy also
Language: Английский
Citations
1
Expert Review of Neurotherapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 9
Published: Oct. 17, 2024
Topiramate is a drug belonging to the second generation of antiseizure arsenal, used treat focal onset seizures without generalization, focal-to-bilateral tonic-clonic seizures, and primary generalized seizures.
Language: Английский
Citations
0
Epilepsia Open, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 29, 2024
Abstract Objective This study investigated the effectiveness and tolerability of brivaracetam (BRV) monotherapy in a large series patients with epilepsy. Method was multicenter, retrospective, observational, non‐interventional 24 hospitals across Spain. Patients aged ≥18 years who started on BRV monotherapy, either as first‐line or following conversion, at least 1 year before database closure were included. evaluated baseline 3, 6 12 months after initiation accordance usual clinical practice these centers. Data collected retrospectively from patients' individual charts by participating physicians. The primary safety endpoints percentage seizure‐free proportion reporting adverse events (AEs) over complete follow‐up period. Retention rates subpopulation analysis (levetiracetam switchers, elderly different etiologies) also investigated. Results A total 276 included (48 228 converted to monotherapy). overall retention rate 89.9% (87.5% for group; 90.4% conversion‐to‐monotherapy group). Seizure‐freedom 77.8% (75% 78.4% AEs occurred 39.5% (35.4% 40.4% Most mild‐to‐moderate. most frequent irritability (12.3%) dizziness (10.1%). leading withdrawal (1.8%) memory problems (1.4%). Similar outcomes terms observed switching levetiracetam, those epilepsy etiologies, patients. Significance effective well tolerated both conversion real‐world setting Plain Language Summary goal medical treatment is ensure best possible patient quality life, maximizing seizure control minimizing medication toxicity. Brivaracetam new‐generation that In our study, reduced seizures had not received other treatments switched previous monotherapy. sensitive (i.e., caused brain tumor injury).
Language: Английский
Citations
0
Published: Jan. 1, 2024
Language: Английский
Citations
0